Clinical Trial Update: A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) [Phase 2]

View source ↗

Summary

Phase 2 study of HTD1801 in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM) completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Nonalcoholic
• Nafld
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• HTD1801

Snippet

Sponsor: HighTide Biopharma Pty Ltd | Conditions: Fatty Liver, Nonalcoholic, NAFLD | Phase 2 | Status: COMPLETED | Results posted: 2021-12-29